An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.

Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger HIMS’ next phase of growth.

Hims & Hers Health Inc HIMS shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their ...

Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...

The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc‘s HIMS peptide ...

The stock is already showing accelerating fundamentals (33% LTM revenue growth, 73% gross margin) plus credible weight-loss distribution via Novo Nordisk’s largest telehealth partner. The market is ...

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health ...

Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as ...